Treatment of non-ST-segment elevation myocardial infarction (NSTEMI) with anticoagulant fondaparinux, as compared to low-molecular-weight heparin (LMWH), had a lower risk of major bleeding events and death both in the hospital and after six months. Researchers analyzed data from a Swedish registry that included 40,616 patients with NSTEMI who received in-hospital treatment with fondaparinux or LMWH between September 2006 through June 2010, with follow-up through ...
No comments:
Post a Comment